Biotech

All Articles

' Scientific intuitiveness' led FDA specialists to back Zevra's rare disease med

.Zevra Therapies' uncommon disease medicine seems to become on the road to approval this loss after ...

Pfizer takes $230M struck after axing failed DMD gene therapy

.Pfizer's stage 3 Duchenne muscle dystrophy (DMD) gene treatment failing has blown a $230 million ho...

AC Immune observes 'landmark' potential in Alzheimer's drug data

.After much more than twenty years of focus on neurodegenerative conditions, Swiss biotech a/c Invul...

GSK loses ph. 2 HPV vaccination over absence of best-in-class prospective

.GSK has broken up a phase 2 individual papillomavirus (HPV) vaccination coming from its own pipe af...

OS Treatments refiles $6M IPO to cash HER2 drug, preclinical ADCs

.OS Therapies will definitely list on the NYSE American supply substitution today via a $6.4 million...

ALX's waning CD47 action rate sends inventory spiraling down

.ALX Oncology's stage 2 stomach cancer cells response price has weakened. After viewing its CD47 blo...

Ionis centers eye condition coming from targets of Roche-partnered possibility after information let down

.One More of Ionis Pharmaceuticals' essential midphase readouts has disappointed requirements, trigg...

Biogen's chief executive officer said no dangerous deals in 2023. He's ready to be strong

.While Biogen's pharma peers are looking for late-stage resources along with little danger, CEO Chri...

Instil refills pipeline in $2B biobucks cope with ImmunOnco

.Instil Bio has been actually a biotech trying to find a pipe after it junked its lead assets over t...

Biogen bows out Denali Alzheimer's collab

.Biogen has restored legal rights to an early Alzheimer's disease plan to Denali Therapeutics, going...